Company
Bristol-Myers Squibb
Bristol-Myers Squibb has 55 drugs tracked on RxWires: 6 post-market, 4 approved, 9 in Phase 3, 18 in Phase 2, 4 in Phase 1/2, 13 in Phase 1.
- Ticker
- BMY
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Aripiprazole | Post-Market | Depressive Disorder, Major |
| TNF Antagonist (enbrel, humire, remicade, cimzia, symponi) | Post-Market | Rheumatoid Arthritis (RA) |
| Apixaban | Post-Market | Non-valvular Atrial Fibrillation |
| Metformin XR | Post-Market | Type 2 Diabetes Mellitus |
| Atazanavir | Post-Market | HIV Infections |
| Xanomeline/trospium chloride | Post-Market | Schizophrenia |
| MONOPRIL | Approved | |
| STILBETIN | Approved | |
| PRINCIPEN | Approved | |
| DEAPRIL-ST | Approved | |
| SAR302503 | Phase 3 | Hematopoietic Neoplasm |
| Aripiprazole oral product | Phase 3 | Pervasive Developmental Disorder |
| Nivolumab | Phase 3 | Non-small Cell Lung Cancer |
| muraglitazar | Phase 3 | Diabetes Mellitus, Type 2 |
| Pumitamig | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) |
| Repotrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung |
| Iza-bren | Phase 3 | Non-Small Cell Lung Cancer |
| BMS-986489 (Atigotatug+Nivolumab) | Phase 3 | Extensive-Stage Small Cell Lung Cancer |
| KarXT | Phase 3 | Bipolar Disorder Type I With Mania or Mania With Mixed Features |
| Luspatercept | Phase 2 | Aplastic Anemia |
| Iberdomide | Phase 2 | Refractory Multiple Myeloma |
| BMS-914392 | Phase 2 | Atrial Fibrillation |
| KOS-862 | Phase 2 | Lung Cancer |
| Navlimetostat | Phase 2 | Solid Tumors |
| HIV Integrase Inhibitor (BMS-707035) | Phase 2 | HIV Infections |
| BMS-790052 | Phase 2 | Hepatitis C Infection |
| MORAb-202 | Phase 2 | Neoplasms, Ovarian |
| Cyclophosphamide | Phase 2 | Pancreatic Cancer |
| Dasatinib | Phase 2 | Leukemia |
| Cabozantinib | Phase 2 | Papillary Renal Cell Carcinoma |
| Erbitux, Paclitaxel & Carboplatin | Phase 2 | Cancer of Head and Neck |
| CC-97540 | Phase 2 | Lupus Erythematosus, Systemic |
| BMS-986036 | Phase 2 | Diabetes Mellitus Type 2 |
| PD-1 blocking antibody | Phase 2 | Nasopharyngeal Carcinoma |
| Paclitaxel | Phase 2 | Non-small Cell Lung Cancer (NSCLC) |
| Nivolumab and Intensity Modulated Radiotherapy (IMRT) | Phase 2 | Non Small Cell Lung Cancer Stage III |
| Laboratory Biomarker Analysis | Phase 2 | Recurrent Plasma Cell Myeloma |
| Cdc7-inhibitor (BMS-863233) | Phase 1/2 | Refractory Hematologic Cancer |
| Dasatinib and Paclitaxel | Phase 1/2 | Breast Cancer |
| Sonication for opening of blood-brain barrier | Phase 1/2 | Glioblastoma |
| Bendamustine | Phase 1/2 | Recurrent Hodgkin Lymphoma |
| CC-122 | Phase 1 | Non-Hodgkin Lymphoma |
| Urelumab | Phase 1 | Colorectal Cancer |
| BMS-986521 | Phase 1 | Healthy Volunteers |
| BMS-986299 | Phase 1 | Advanced Cancer |
| rosuvastatin | Phase 1 | Healthy Participants |
| galantamine | Phase 1 | Alzheimer Disease |
| Carfilzomib | Phase 1 | Recurrent Plasma Cell Myeloma |
| Anti-CXCR4 (BMS-936564) | Phase 1 | Multiple Myeloma |
| BMS-986177 | Phase 1 | Thrombosis |
| BMS-833923 (XL139) | Phase 1 | Hedgehog Pathway |
| BMS-986322 | Phase 1 | Healthy Participants |
| BMS-914832 | Phase 1 | Atrial Fibrillation |
| Venetoclax | Phase 1 | AML |
| DCV/ASV/BMS-791325 | Not Applicable | Hepatitis C |
Latest
- bristol-myers squibb filed 8-K
- bristol-myers squibb filed 8-K
- bristol-myers squibb filed 8-K
- bristol-myers squibb filed 8-K
- bristol-myers squibb filed 8-K
Follow Bristol-Myers Squibb on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.